ClinicalTrials.gg
RecruitingNCT05778110MOSS-THINKUpdated May 3, 2023

Multiomic Analysis of Traumatic Brain Injury and Hypertension Intracranial Hemorrhage Lesion Tissue

An observational study in Brain Injury Traumatic Severe and Intracranial Hemorrhage, Hypertensive, sponsored by RenJi Hospital. Recruiting at 1 site in China. Open to participants aged 16 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-05-03.

Sponsored by RenJi Hospital · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2024, 2 years 7 months ago, but the record still lists the study as recruiting.
  • Started Apr 2023; still recruiting 3 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
10
Ages
16 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Intracranial Hemorrhage, Hypertensive with a site in China — 4 open to participants now, 4 under way, none of them phase 3. Intracranial Hemorrhage, Hypertensive · China.

Started
2023
the only one that year
Observational
Only one
of the 11
Registered
9th of 11
by date
Lead sponsor
1 of 11
RenJi Hospital

Among the 11 studies in Intracranial Hemorrhage, Hypertensive with a site in China, this one is the only one that started in 2023, is the only observational one, and was the 9th registered.

Intracranial Hemorrhage, Hypertensive

23 studies on the registry are indexed under Intracranial Hemorrhage, Hypertensive; 8 are open to participants now.

Browse Intracranial Hemorrhage, Hypertensive studies →

Open to participants now

4 of the 11 studies in Intracranial Hemorrhage, Hypertensive with a site in China are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1 Intracranial Hemorrhage, Hypertensive study recruiting now, none set no upper age limit and 1 stops at 75 or younger; 1 takes children under 18; none take healthy volunteers.

This study: 16 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Intracranial Hemorrhage, Hypertensive with a site in China, or all of them as a file.
02

Study summary

The goal of this experimental observation study is to figure out differently expressed biomarkers in lesion tissues in traumatic brain injury or hypertension intracranial hemorrhage patients. The main questions it aims to answer is:

  • Which RNA, protein and metabolites are differently expressed in lesion tissues?
  • What molecular mechanism is participated in TBI or ICH? Participants will be treated by emergency operation, and their lesion tissues will be collected during the operation.
03

Conditions studied

  • Brain Injury Traumatic Severe
  • Intracranial Hemorrhage, Hypertensive

Keywords

  • Traumatic brain injury
  • Hypertensive intracranial hemorrhage
  • Multiomic analysis
  • Biomarker
  • Molecular mechanism
04

Who can participate

Ages eligible
16 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with severe traumatic brain injury or hypertensive intracranial hemorrhage.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age >18 and \<65
  2. Within 12 hours after brain injury
  3. GCS ≥3 and ≤8
  4. Closed brain injury with frontotemporal contusion or basal ganglia intracranial hemorrhage
  5. Need emergency intracranial hematoma evacuating operation
  6. Patient's agents are informed and consent the research

Exclusion criteria

Exclusion Criteria:

  1. With TBI, stroke, ICH or intracranial tumor history
  2. Death within 24 hours
  3. state
  4. Severe organ dysfunction
  5. Complicated infective disease
  6. Pregnant
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
10 participants (estimated)
Patient registry
No

Groups and cohorts

  • TBI

    Patients with traumatic brain injury.

    Other: Type of disease

  • ICH

    Patients with hypertensive intracranial hemorrhage.

    Other: Type of disease

Interventions

  • OtherType of disease

    Different types of pathogen: brain injury by trauma or intracranial hemorrhage due to hypertension.

06

What researchers measure

Primary outcomes

  1. RNA biomarkers in TBI or ICH patients' lesion tissues assessed by transcriptome bioinformatic analysis

    Patients' lesion tissue will be collected during hematoma evacuation. Then these tissues will be immediately prepared to be detected through transcriptome sequencing. The results of transcriptome sequencing will be further analyzed by bioinformatic analysis to reveal different RNA expressions in lesion tissues of severe TBI and ICH patients as the potential biomarkers.

    Time frame: Immediately after collecting tissues

  2. Protein biomarkers in TBI or ICH patients' lesion tissues assessed by proteomic bioinformatic analysis

    Patients' lesion tissue will be collected during hematoma evacuation. Then these tissues will be immediately prepared to be detected through proteomics mass spectrometry. The results of proteomic will be further analyzed by bioinformatic analysis to reveal different protein expressions in lesion tissues of severe TBI and ICH patients as the potential biomarkers.

    Time frame: Immediately after collecting tissues

  3. Metabolite biomarkers in TBI or ICH patients' lesion tissues assessed by metabolomic bioinformatic analysis

    Patients' lesion tissue will be collected during hematoma evacuation. Then these tissues will be immediately prepared to be detected through metabolomic mass spectrometry. The results of metabolomic will be further analyzed by bioinformatic analysis to reveal different metabolite expressions in lesion tissues of severe TBI and ICH patients as the potential biomarkers.

    Time frame: Immediately after collecting tissues

07

Study locations

1 of 1 sites recruiting
  • Brain Injury Center, Renji Hospital, School of Medicine, Shanghai Jiao Tong University
    Shanghai, Shanghai, China
    Recruiting
    • Junfeng Feng · Contact+8613611860825
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2023 (actual). Primary completion is estimated for Mar 2024, 11 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2023
First posted
Mar 21, 2023
StartActual
Apr 1, 2023
Primary completionEst.
Mar 31, 2024
CompletionEst.
Dec 31, 2024
Last update
May 3, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 3, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05778110
Lead sponsor
RenJi Hospital
Responsible party
Junfeng Feng (Director of Brain Injury Center, RenJi Hospital) — Principal investigator
First posted
Mar 21, 2023
Start date
Apr 1, 2023
Primary completion
Mar 31, 2024 (estimated)
Completion
Dec 31, 2024 (estimated)
Last update
May 3, 2023

Study contacts

Zhenghui He, MD
Contact
hezhenghui8@hotmail.com
+8613585916217

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion